The efficacy of AL and ASAQ remains high in Togo, and both drugs are well tolerated.
artemisinin-based combination therapy (ACT)
Artemisinin-based combination therapy with the AMFm logo was accessible and affordable for most people seeking treatment from health facilities and LCS shops in rural areas.
A clinical episode of vivax malaria was associated with subsequent sub-clinical parasitaemia.
Patients’ lack of knowledge and health sector drawbacks affected side effect reporting on ACT.
Though malaria RDT use in medicines outlets was largely uncommon, both community members and medicine outlet practitioners welcomed its use.
Therapeutic efficacy of AS-AQ and AL remains over 90 % in the forest and savannah zones of Ghana.
Malaria currently causes more harm to human beings than any other parasitic disease, and disproportionally affects low-income populations.
ACT exposure in early pregnancy was more common than quinine exposure.
This is the first study to assess adherence to an FDC of ACT under real treatment conditions in a context of high instability.
Majority of patients was successfully followed up by telephone and reported the most AEs.